Literature DB >> 28856141

Diagnosis and treatment of pulmonary cavity after liver transplantation.

Yongxiang Xia1,2, Haoming Zhou1,2, Feipeng Zhu3, Wei Zhang3, Chen Wu1,2, Ling Lu1,2.   

Abstract

BACKGROUND: Although the outcomes have improved in the current era, pulmonary infection remains a significant post-transplant complication in liver transplant (LT) recipients. Pulmonary infection with cavity formation often leads to higher mortality rates after LT. We wished to investigate the diagnosis and treatment of pulmonary cavity (PC) formation after LT.
METHODS: We evaluated (retrospectively) five cases of PC formation, shown on CT scans of the chest after LT, by analyzing imaging features, diagnosis, treatment, liver function, and the concentration changes and efficacy of immunosuppressants.
RESULTS: According to the results from the CT scan, serum Aspergillus galactomannan (GM) assay, the purified protein derivative (PPD) skin test, and the sputum smears and blood culture, three cases were diagnosed with Aspergillus infection, and the other two cases were diagnosed with Mycobacterium tuberculosis infection. Liver function and FK506 concentration were monitored during treatment. Antibiotics used for treatment of Aspergillus and Mycobacterium tuberculosis infections affected liver function and FK506 concentration. However, after adjustment of drug doses, antibiotic treatment was tolerated in all patients. Four cases were cured, but 1 patient died of Aspergillus infection.
CONCLUSIONS: Distinguishing between Aspergillus infection and Mycobacterium tuberculosis infection for PCs after liver transplantation (LT) using a CT scan is difficult. The diagnosis can be confirmed using clinical characteristics, sputum culture, GM assay, PPD, and sputum smears. Early diagnosis and treatment could lead to a better prognosis.

Entities:  

Keywords:  Aspergillus; Pulmonary cavity (PC); liver transplantation (LT); tuberculosis (TB)

Year:  2017        PMID: 28856141      PMCID: PMC5555993          DOI: 10.21037/atm.2017.05.14

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  17 in total

Review 1.  Respiratory complications after solid-organ transplantation.

Authors:  Pınar Zeyneloğlu
Journal:  Exp Clin Transplant       Date:  2015-04       Impact factor: 0.945

2.  Radiological and clinical findings of pulmonary aspergillosis following solid organ transplant.

Authors:  Y S Park; J B Seo; Y K Lee; K H Do; J S Lee; J-W Song; K S Song
Journal:  Clin Radiol       Date:  2008-03-04       Impact factor: 2.350

3.  Clinical outcomes of Pneumocystis carinii pneumonia in adult liver transplant recipients.

Authors:  Y-I Choi; S Hwang; G-C Park; J-M Namgoong; D-H Jung; G-W Song; T-Y Ha; D-B Moon; K-H Kim; C-S Ahn; S-G Lee
Journal:  Transplant Proc       Date:  2013-10       Impact factor: 1.066

4.  Invasive Pulmonary Aspergillosis-mimicking Tuberculosis.

Authors:  Sung-Han Kim; Mi Young Kim; Sun In Hong; Jiwon Jung; Hyun Joo Lee; Sung-Cheol Yun; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo
Journal:  Clin Infect Dis       Date:  2015-03-16       Impact factor: 9.079

5.  Selected pharmaceutical excipient prevent isoniazid and rifampicin induced hepatotoxicity.

Authors:  Tung-Yuan Shih; Shan-Chu Ho; Cheng-Huei Hsiong; Tien-Yu Huang; Oliver Yoa-Pu Hu
Journal:  Curr Drug Metab       Date:  2013-07       Impact factor: 3.731

6.  High-resolution CT findings in patients with pulmonary tuberculosis: correlation with the degree of smear positivity.

Authors:  Fatih Ors; Omer Deniz; Ugur Bozlar; Seyfettin Gumus; Mustafa Tasar; Ergun Tozkoparan; Cem Tayfun; Hayati Bilgic; Brydon J B Grant
Journal:  J Thorac Imaging       Date:  2007-05       Impact factor: 3.000

7.  Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report.

Authors:  S Bhaloo; G V R Prasad
Journal:  Transplant Proc       Date:  2003-11       Impact factor: 1.066

Review 8.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.

Authors:  Ellen Hulskotte; Samir Gupta; Fengjuan Xuan; Marga van Zutven; Edward O'Mara; Hwa-Ping Feng; John Wagner; Joan Butterton
Journal:  Hepatology       Date:  2012-10-14       Impact factor: 17.425

10.  Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.

Authors:  Chiyo K Imamura; Kenichi Furihata; Shinichiro Okamoto; Yusuke Tanigawara
Journal:  J Clin Pharmacol       Date:  2015-10-08       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.